In a recent move that underscores its innovative approach to biotechnology, New York-based Ancilia Biosciences has successfully closed a $4.2 million financing round. This funding aims to propel the development of bacterial products and therapies that are not only unique but immune to viruses, enhancing their therapeutic potential.

‍

Read more.